NDAINHALATIONPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
6/8 — Strong
AIRDUO DIGIHALER (fluticasone propionate and salmeterol) by Teva is salmeterol. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AIRDUO DIGIHALER is a fixed-dose combination inhaler containing fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) delivered via a digital-enabled powder device. It treats asthma by reducing airway inflammation through corticosteroid action and providing sustained bronchodilation via LABA activity. The formulation targets patients requiring combination maintenance therapy for moderate-to-severe asthma control.
$0.648MPart D
Peak14.5 years to LOEProduct is at peak lifecycle stage with modest Part D utilization; brand team focus is on maintaining market position rather than growth expansion.
Mechanism of Action
salmeterol. The mechanisms of action described below for the individual components apply to this combination product. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices.…
Worked on AIRDUO DIGIHALER at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.